Very-early-onset Inflammatory Bowel Disease in an Infant with a Partial RIPK1 Deletion

The monogenic causes of very-early-onset inflammatory bowel disease (VEO-IBD) have been defined by genetic studies, which were usually related to primary immunodeficiencies. Receptor-interacting serine/threonine-protein kinase-1 (RIPK1) protein is an important signalling molecule in inflammation and cell death pathways. Its deficiency may lead to various clinical features linked to immunodeficiency and/or inflammation, including IBD. Here, we discuss an infant with malnutrition, VEO-IBD, recurrent infections and polyathritis who has a homozygous partial deletion in RIPK1 gene.


Introduction
Inflammatory bowel disease (IBD) is a collective term for a group of chronic inflammatory disorders of the digestive tract.The etiology involves both genetic and environmental factors, though in rare cases, IBD can be caused by an underlying monogenic immunodeficiency.Very-early-onset (VEO) IBD is defined by a disease onset before six years of age [1] and characterized by a higher proportion of monogenic cases as compared to later-onset forms (an estimated 15-20% of VEO-IBD) [2].So far, more than 70 genes have been linked to monogenic VEO-IBD [3,4].Patients with VEO-IBD generally have a poor prognosis and are unresponsive to treatment, except for certain immunodeficiencies [3][4][5][6].It is critical to identify underlying genetic abnormalities in order to evaluate treatment options.If the underlying problem only affects cells originating from the hematopoietic system, it can be treated with allogeneic hematopoietic stem cell transplantation (HSCT), but intrin-it was insufficient (100 g/month) in the last three months.His parents were first-degree relatives, and the patient had third-degree relatives with Behçet's Disease (Fig. 1).The physical examination revealed acute moderate malnutrition (weight and length for age z-score − 2.9 and − 1.5, respectively, and weight for length z-score − 2.8), long and curly eyelashes, oral moniliasis, high palate, an aphthous ulceration on the soft palate, bilateral coarse breath sounds and rhonchi, swelling and tenderness on the 3rd and 4th metacarpophalangeal and proximal interphalangeal joints of both hands.His laboratory tests revealed hypochromic microcytic anemia (Hemoglobin: 8.1 g/dL, mean corpuscular volume: 67 fL), thrombocytosis (669 000/mm 3 ), hypoalbuminemia (3 g/dL), and elevated C-reactive protein [73.9 mg/L (N: 0-5 mg/L)].Erythrocytes and leucocytes were positive in stool examination.Microbiological tests for cryptosporidium PCR and other diarrheal agents were negative.Sweat chloride test and thyroid function tests were normal.Advanced immunological work-up revealed normal peripheric blood leucocytes, lymphocyte activation with phytohemagglutinin (PHA) and oxidative burst test, except for decreased numbers of CD4 + lymphocytes and natural killer cells (Table 1).Immunoglobulin levels were in normal ranges (Table 1) and specific IgE for cow's milk and egg yolk were negative.Abdominal ultrasonography and upper gastrointestinal endoscopy were normal, but colonoscopy revealed small aphthous ulcers, hyperemia, oedema, fragility on ileocecal valve and dominantly on distal colonic mucosa.Histopathology revealed mild esophagitis, Helicobacter pylori negative chronic non-atrophic gastritis, mild active colitis with cyrptitis, ulceration and faint cyrpt distortion in distal colonic mucosa (Fig. 2).Cytomegalovirus PCR was negative in blood and tissue examination.Small bowel follow-through radiologic examination was normal.Computed tomography of the chest revealed slight central ground-glass opacity and centriaciner micronodules on the upper lobes of bilateral lungs.Bronchoscopy was normal except for white-coloured mucoid secretion coming from both main bronchi and very mild stenosis of right bronchus intermedius.Bronchoalveolar lavage culture was positive for Klebsiella pneumonia.
Recurrent severe infections, growth retardation, VEO-IBD, reduced CD4 + T cells and consanguineous marriage suggested that a primary immunodeficiency may be the underlying cause, and genetic analysis was planned in order to identify the underlying defect.Rheumatological examination revealed normal anti-nuclear antibody, IgD, complement levels, a negative pathergy test but a homozygous p.Glu148Gln mutation (E148Q) in exon 2 of the MEFV gene by direct sequencing analysis of the PCR-restricted fragment length polymorphism (RFLP) protocol.Ophthalmological examination was normal.There were no specific  After one month of high-dose steroid treatment, there was no improvement in his clinical and laboratory findings and no weight gain.He was hospitalised for three times in the following six months due to lower respiratory tract infection, fever and diarrhoea.Therefore, immunosuppressive treatment was ceased as there was no beneficial effect.After one month, he was hospitalized for vomiting, diarrhoea, perianal abscess and perianal fistula, maculopapular rash, tenderness and limitation in the movement of the left arm.Total parenteral nutrition and broad-spectrum antibiotics were given, and drainage of the perianal abscess and fistulectomy were performed.He developed catheter-related Klebsiella pneumonia and Enterococcus feacalis infection, complicated with disseminated intravascular coagulation and intracranial haemorrhage.He was followed in the intensive care unit for five months under supportive treatment including mechanical ventilation, but unfortunately, he died at the age of two years due to Acinetobacter boumanni sepsis and multiorgan failure.After his death, whole-exome sequencing revealed a homozygous 22,736 bp-deletion encompassing the exons 8-11 of RIPK1 and exon 1 of the consecutive gene BPHL that was validated using PCR and Sanger sequencing (Fig. 3A and B).PCR and Sanger sequencing of cDNA synthesized from mRNA from a patient-derived EBV-immortalized B-cell line shows that the deletion leads to the expression of RIPK1-BPHL fusion transcripts.We could detect two differently spliced fusion transcripts, both of which are predicted to result in a frameshift and stopgain, leading to a premature stop in RIPK1 exon 6 and BPHL exon 3, respectively.The fusion RIPK1-BPHL transcripts and the positions of the introduced stop codons are illustrated in the supplementary Fig. 3 C-E.This indicates that that no functional RIPK1 protein is expressed in the patient's cells because, even if the mutant transcript were to evade nonsense-mediated decay, the predicted protein would be truncated within or shortly after the RIPK1 kinase domain.
The critical role of RIPK1 in the survival of intestinal epithelial cells has been demonstrated in RIPK1-deficient mice that had developed intestinal pathology via inhibition of caspase-8-mediated apoptosis [8,9].Whereas intestinal cell apoptosis seems to play a crucial role in mice, the symptoms in RIPK1 deficient humans are predominantly mediated by dysregulated immune signalling [11,12].
Biallelic loss-of-function RIPK1 variants, have been linked to severe immunodeficiency, early-onset inflammatory bowel disease and arthritis [7].While impaired T-and B-cell differentiation, significant lymphopenia, and 2) and BPHL (NM_004332.4),respectively.The deletion was called from whole-exome data based on coverage values using the ExomeDepth software [10].Since the breakpoints were located outside the targeted regions, their exact position could not be inferred from the whole-exome data alone.As illustrated by the IGV screenshot, the density of off-target reads mapped to the introns 7-8 (RIPK1) and 1-2 (BPHL) were visibly sparser in the patient compared to controls.Primers were designed based on the assumption that the breakpoint was located near the points where the read density starts to decrease (primer binding sites are indicated with green arrows).(C) Chromatogram showing the breakpoint of the cDNA fusion transcript between RIPK1 and the following gene BPHL.cDNA was synthesized from mRNA from B-cell lines derived from the patient and a healthy control.PCR and Sanger sequencing showed that the deletion leads to a fusion transcript between RIPK1 and BPHL in the patient.(D) Gel electrophoresis of the products from PCR 1 (primers binding in RIPK1 exon 1 and BPHL exon 3; forward:5'GGAAGGTGTCTCTG TGTTTCCA3', reverse: 5'GAGGTCCAAAATCAGTCTCTCCA3') and PCR 2 (primers binding in RIPK1 exon 6 and BPHL exon 7; forward: 5'GCTCTGCTGGGAAGCGAAT3', reverse: 5'GGTTGT-GTTTGCCTTCTGGC3').Sanger sequencing showed that the multiple bands correspond to different splice variants, caused by skipping of RIPK1 exon 5 (PCR 1, 732 bp product) and the partial skipping of BPHL exon 5 (PCR 2, 763 bp product).The 443 bp band in PCR 2 is due to unspecific amplification of ABCB8 cDNA in both the patient and the control subject.In the healthy donor, no other products were amplified due to the absence of a fusion transcript.(E) Illustration of the wildtype transcripts and the mutant fusion transcripts in the patient.All transcripts identified in the patient are predicted to lead to a frameshift and premature stop in either RIPK1 exon 6 or BPHL exon 3, depending on whether or not RIPK1 exon 5 is skipped.In a proportion of the transcripts, part of BPHL exon 5 is skipped (indicated in grey).Since RIPK1 exon 5 and BPHL exon 5 were not included in the same amplicons, we do not know if the partial BPHL exon 5 skipping occurred in the transcripts including RIPK1 exon 5, excluding RIPK1 exon 5, or both RIPK1 as well as the first exon of the adjacent BPHL gene (Fig. 3A).This deletion comprises more than half of the RIPK1 coding sequence and leads to the expression of two differently spliced fusion transcripts between RIPK1 and BPHL in a patient-derived B-cell line.Both detected fusion transcripts contain a frameshift followed by a premature stop codon in RIPK1 exon 6 or BPHL exon 3, respectively.Hence, the patient is predicted to express no functional RIPK1 protein (Fig. 3C, D and E).Given that the phenotype of the patient is consistent with previous reports of RIPK1 deficiency, the deletion was considered causative.Notably, both the detection of large copy-number variants, from wholeexome data as well as their validation with PCR and Sanger is challenging.Hence, such variants might evade detection during routine diagnostic testing using exome sequencing.Our approach to design suitable primers for the validation in this patient is illustrated in Fig. 3B.To our knowledge, this is first report of a pathogenic deletion affecting these two genes.It has been suggested that bilalleic loss of BPHL is tolerated [20].Therefore, an impact of the partial BPHL deletion on the patient's phenotype was considered unlikely.BHPL encodes Biphenyl hydrolase like, a serine hydrolase that converts valacyclovir to acyclovir and valganciclovir to ganciclovir [21].Since the patient was not given such antiviral treatment, it is unkown whether the BPHL exon 1 deletion might have impacted the response to treatment with these drugs.Moreover, a homozygous MEFV p.Glu148Gln missense variant (E148Q) was detected in our patient.MEFV encodes pyrin, which takes part in controlling the inflammation process, regulates IL-1b and nuclear factor kappa beta (NF-kB) activation and, inhibits Caspase-1 activation and apoptosis.Defective pyrin leads to Caspase-1 activation and excessive release of IL-1β [22,23].It has been reported that patients with the p.Glu148Gln substitution respond well to colchicum treatment, which reduces IL-1β production [24,25].Aydın F et al. [24] reported E148Q alteration leads to similar clinical findings to M694V mutations, but a milder disease and good response to colchium treatment, similar to the report of Topaloglu R et al. [26].They concluded E148Q should be considered as a disease-causing mutation [24,26].On the other hand, it should be noted that a pathogenic effect of MEFV p.Glu148Gln is still being debated, since the variant is relatively common in the general population (with an allele frequency of approximately 0.3 in the East and South Asian population according to the Genome Aggregation Database 2.1.1)and, hence, meets the standalone criterion BA1 for benignity according to the ACMG variant interpretation guidelines [27].Urgancı N et al. [28] reported heterozygous E148Q mutation was the most common MEFV gene mutation among 597 patients (2-18 years old age) diagnosed ulcerative colitis and Crohn disease, but the relation of clinical course of the diseases and mutation decreased production of proinflammatory cytokines such as IL-6, TNF, and IL-12 lead to immunodeficiency, active inflammasome formation and necroptosis might be related to the inflammatory component of the disease [9][10][11][12]15].Interestingly, recent studies show that variants which impair the caspase-8-mediated RIPK1 cleavage, confer a gain-offunction effect, leading to the autosomal dominant cleavage-resistant RIPK1-induced autoinflammatory (CRIA) syndrome [15][16][17][18].
To our knowledge, 16 patients (age at onset 1 day − 4 years old age) with autosomal recessive RIPK1 deficiency have been reported to date.They presented with colitis and recurrent infections, also some of them had polyarthritis, aphthous ulcers, and perianal disease that comparable to our patient, because of the critical role of RIPK1 in controlling human immune and intestinal homeostasis [7-9, 15, 19].
Patients with RIPK1 deficiency were found to have increased pro-inflammatory cytokine IL-1β and decreased IL-10 secretion, a critical cytokine in regulation of the immune response in the gut [7].Poor treatment response was reported to immunosuppressive treatments, such as azathioprine, corticosteroids, infliximab, IL-1 receptor antagonist, and also hematopoietic stem cell transplantation (HSCT).On the other hand, several patients were reported to be alive only with intravenous immunoglobulin, antifungal and antibiotic treatment.There was no relation between treatment success and age or clinical presentation of the patients [7-9, 15, 19].
The ability of HSCT to treat this disease is still unknown.Given RIPK1's functions in regulating both immunological and epithelial responses, performing HSCT to treat these sufferers should be taken with caution since it may improve immunodeficiency [7-9, 15, 19].Cuchet-Lourenco et al. [7] reported three patients with RIPK1 deficiency who underwent HSCT.Of them, intestinal symptoms and arthritis of the 30-month-old age patient improved but antibiotic treatment had been continued for the chronic lung disease.The older patients aged at 12-year-old and 13-year-old patient died due to multiorgan deficiency and severe disseminated infection respectively [7].These different clinical manifestations and response to treatment might be related to genotype-phenotype correlations, variable penetrance, or secondary factors such as microbiome [8].With the developing genetic and functional studies, various predisposing factors that may lead to enhancement of immune dysregulation can be determined in the future.
Here, we report an infant with a severe form of infantile IBD presenting with malnutrition, recurrent severe infections, polyarthritis, and perianal fistula tract.Wholeexome sequencing followed by PCR and Sanger sequencing revealed and confirmed a homozygous deletion in RIPK1, spanning 22.7 kb and covering the last four coding exons of is still under debate.Unfortunately, we did not observe any beneficial effect of colchicum on the clinical course of the patient.Therefore, and due to the phenotype of the patient that was highly similar to previous reports, we consider the partial RIPK1 deletion the likely cause of disease, although a modifying effect of MEFV p.Glu148Gln can not be ruled out.
In conclusion, despite the widespread utilization of genetic testing, it still has limitations in determining a specific etiology, which may prevent the decision on the appropriate treatment for the patients with VEO-IBD and associated immunodeficiencies.RIPK-1 protein deficiency and the possibility of larger copy-number variants evading detection during routine testing should be considered in the presence of VEO-IBD, polyarthritis, and recurrent infections.

Fig. 1
Fig. 1 Pedigree of the patient.Grey box: Behçet Disease.Black arrow: The patient with RIPK1 deficiency

Table 1
The immunological work-up of the patient